Lenalidomide in Cancer Treatment
Author Information
Author(s): Bartlett J B, Tozer A, Stirling D, Zeldis J B
Primary Institution: Celgene Corporation
Hypothesis
Lenalidomide, an immunomodulatory drug, is effective in treating multiple myeloma and myelodysplastic syndromes.
Conclusion
Lenalidomide shows significant efficacy in treating multiple myeloma and myelodysplastic syndromes, with a favorable safety profile.
Supporting Evidence
- Lenalidomide has shown a 61.2% overall response rate in combination with dexamethasone for multiple myeloma.
- Patients with myelodysplastic syndromes showed a 56% response rate to lenalidomide treatment.
- Lenalidomide is associated with fewer side effects compared to thalidomide.
Takeaway
Lenalidomide is a medicine that helps people with certain types of blood cancer feel better and live longer.
Methodology
The review summarizes clinical studies and trials involving lenalidomide in multiple myeloma and myelodysplastic syndromes.
Potential Biases
Potential bias due to the involvement of the drug manufacturer in the studies.
Limitations
The review does not provide detailed data on all studies and may not cover all potential side effects.
Participant Demographics
Patients with multiple myeloma and myelodysplastic syndromes, including those who are relapsed or refractory.
Statistical Information
P-Value
P=0.0023
Statistical Significance
p<0.0015
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website